ORIC241115C25000
- 0.00
- 0.000.00%
Oric Pharmaceuticals Newsroom
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Express News | Oric® Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Wells Fargo Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $20
Oric Pharmaceuticals Initiated at Buy by Jones Trading
Express News | Oric Pharmaceuticals, Inc. : Wells Fargo Initiates Coverage With Overweight Rating and Target Price $20
JonesTrading Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $17
Oric Pharmaceuticals Presents Data on ORIC-114
Express News | ORIC Pharmaceuticals Announced The Presentation Of A Poster Highlighting ORIC-114, A Brain Penetrant, Orally Bioavailable, Irreversible EGFR/HER2 Inhibitor, To Treat EGFR Exon 20 Insertions And Other Atypical Mutations
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to It's Board of Directors
ORIC Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Buy Rating Affirmed for Oric Pharmaceuticals Amid Promising Collaborations and Strategic Clinical Advances
OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration
Oric Pharmaceuticals (ORIC) Gets a Buy From Wedbush
Express News | Cantor Fitzgerald Reiterates Overweight on ORIC Pharmaceuticals
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $20
Stifel Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $20
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Optimistic Outlook on Oric Pharmaceuticals' Cancer Therapy Pipeline and Strategic Partnerships